Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research groups

Ling Felce

MBiochem, DPhil


Postdoctoral Researcher

I completed my DPhil in Clinical Pharmacology from the Department of Oncology, University of Oxford, where the focus of my thesis was the production and testing of B-cell targeting cancer vaccines based on different viral vectors. During the course of my research, I became interested in cancer immunology and the tumour microenvironment.

My first postdoctoral project was undertaken with Professor Alison Banham (NDCLS/RDM) where I investigated the targets of transcription factor FOXP1 in diffuse large B-cell lymphoma (DLBCL). In patients with DLBCL, FOXP1 can be used as a marker for poor prognosis, and may play a role in downregulating immune surveillance in tumours. I used CRISPR-Cas9 gene editing technology to knockout FOXP1 expression in a murine lymphoma cell line, and subsequently conducted tumour studies in vivo and carried out RNA-Seq to examine differential gene expression between parental and FOXP1-knockout cells.

In 2017 I joined Dr Gillian Farnie’s group at the Botnar Research Centre, where my research is focused on novel protein families, such as YEATS and Nudix in cancer. I am currently looking into the role of MLLT1 histone reader in breast cancer by altering MLLT1 protein levels/function through CRISPR-Cas9 knockouts and small molecule inhibition, and using next generation sequencing (RNA-Seq and ChIP-Seq) to understand how MLLT1 alters global gene expression to drive tumourigenesis and metastasis in breast cancer.

Key publications

Recent publications

More publications